Browsing: Lilly

Danish drugmaker Novo Nordisk has sued rival Eli Lilly, alleging the U.S. pharmaceutical giant is misleading consumers with ad campaigns that the company’s weight-loss and diabetes drugs are superior to Novo’s competing products, Reuters reported

On Tuesday, Novo Nordisk initiated legal action against Eli Lilly, claiming the company’s promotional efforts for its popular obesity and diabetes medications intentionally deceive patients regarding their greater effectiveness compared to Novo’s competing products. The company objects to national advertisements that reference what it describes as obsolete study data, using those comparisons to pit the…

Novo Nordisk, maker of the popular medications Ozempic and Wegovy, filed a lawsuit Tuesday against the pharmaceutical company Eli Lilly, accusing it of making deceptive advertising claims about its weight-loss drug Zepbound

Novo Nordisk sued Eli Lilly on Tuesday, accusing its rival of misleading consumers by claiming Lilly’s drugs work better than Novo’s competing treatments

LONDON, July 21 (Reuters) – Novo Nordisk sued rival Eli Lilly in a U.S. federal court on Tuesday, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo’s drugs

Novo Nordisk said Eli Lilly’s ads uses outdated research and leave out important information, which could mislead consumers

Novo NordiskNVO and Eli LillyLLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and Rybelsus for type II diabetes, and as Wegovy for weight management

Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo’s

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly’s advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo’s latest higher-dose Wegovy and Ozempic treatments. Novo is seeking to halt the advertising, require corrective marketing, and recover damages as the companies compete in the growing obesity…

The lawsuit, filed in the U.S. District Court for the District of New Jersey, accuses the competitor of violating both state and federal false advertising and unfair competition laws